Compare Ascendis Pharma A/S (ASND) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Hershey Co — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Hershey Co trades at $175.81 (market cap $35.23B). The key difference: Hershey Co is the larger of the two by market cap, and Hershey Co pays a 3.34% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HSY | |
|---|---|---|
Market Cap | $17.74B | $35.23B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $236.28 |
52-Week Low | $163.32 | $162.31 |
Enterprise Value | $18.11B | $40.03B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HSY trades at $173.66, up 1.17% with recent earnings beats and easing cocoa costs supporting fundamentals. Technicals are bearish with resistance at $175, while valuation metrics like a P/E of 32.34 suggest premium pricing. The company maintains strong cash flow and a 3.22% dividend yield, with Q2 2026 earnings due July 30, 2026, as a key catalyst.
Outlook: Upside exists to the $210.33 consensus target if margin recovery continues, but high debt and volatile input costs pose risks. Analyst sentiment is cautious with 65.7% hold ratings, reflecting balanced growth and valuation concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
